Variable. All other factors were considered as binary variables. Factors significant on univariate analysis were entered into multivariate and interaction (with IREG+) analyses. Hazard ratio = HR. Confidence interval = CI. Lymph node, LN. (DOC) Table S7 Cox proportional hazard analysis of overall survival for 232 colon cancer patients. The indicated modelAcknowledgmentsWe thank Dr. Samuel Hellman for Licochalcone-A site helpful discussions of this manuscript.Author ContributionsConceived and designed the experiments: SPP TZ RFS WZ NNK JGNG RRW. Performed the experiments: SPP TZ RFS MF EL MAB HJM HL TED SP SAK HGS WZ NNK. Analyzed the data: SPP TZ RFS WZ NNK JGNG RRW. Contributed reagents/materials/analysis tools: SPP TZ RFS WZ NNK JGNG RRW. Wrote the paper: SPP TZ RFS NNK JGNG RRW.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in North America with an overall 5-year survival rate of ,5 [1]. Previous PDAC microarray studies have revealed novel genes associated with disease progression. One of these was lipocalin-2 
(LCN2), which was significantly overexpressed in PDAC cell lines and primary tumors compared to normal pancreas [2,3]. LCN2 expression was also enhanced following KRAS oncogene expression in the normal human pancreatic duct epithelial cell line H6c7 [4]. LCN2 is also known as neutrophil gelatinase-associated lipocalin (NGAL) and belongs to a diverse family of lipocalins [5]. It binds covalently and non-covalently with a wide range of macromolecules including small hydrophobic ligands, soluble extracellular macromolecules, and iron [6]. Its expression is upregulated in epithelial cells under inflammatory conditions including appendicitis, organ damage, and pancreatitis [5,7]. MedChemExpress 16960-16-0 Overexpression of LCN2 has also been observed in a number of cancer types including breast, lung, ovary, thyroid, esophageal, and PDAC [8?2]. However, the precise role of LCN2 in cancer has not been completely 15755315 defined. The covalent complex of LCN2 and MMP-9 has been associated with enhancing invasion andmetastasis in breast cancer [12?4], poorer clinical outcome and improved migration in gastric cancer, [15,16], and increased depth of tumour invasion in esophageal cancer [11]. In addition to its role in regulating MMP-9 activity, LCN2 has also been shown to promote cell survival in A549 and MCF-7 cells when treated with phosphoinositide-dependent kinase 1 (PDK1) inhibitors [17]. Its function in iron binding and transport has recently been shown to block the induction of the pro-apoptotic protein Bim and activation of caspase-9 which attenuates apoptosis [10]. The function of LCN2 in PDAC remains unclear. In this study, we examined the expression of LCN2 in precursor lesions of various grades and tumour tissue samples to correlate expression with the pathogenesis of PDAC. We also utilised tissue culture and mouse xenograft models to examine the function of LCN2 in PDAC. Here, we report that LCN2 contributes to the invasive, angiogenic, and drug resistant phenotypes in pancreatic cancer.Materials and Methods Cell Culture and in vitro AssaysHuman PDAC cell lines, BxPC3, HPAF-II and PANC1 were obtained from the American Type Culture Collection (Manassas,LCN2 in Pancreatic CancerVA). 
BxPC3 was cultured in RPMI media supplemented with 10 FBS. HPAF-II and PANC1 cells were cultured in DMEM media supplemented with 10 FBS. H6c7, H6c7 KRASG12V, and H6c7KrT cell lines were generated as previously described [4]. Invasion assays were performed as pre.Variable. All other factors were considered as binary variables. Factors significant on univariate analysis were entered into multivariate and interaction (with IREG+) analyses. Hazard ratio = HR. Confidence interval = CI. Lymph node, LN. (DOC) Table S7 Cox proportional hazard analysis of overall survival for 232 colon cancer patients. The indicated modelAcknowledgmentsWe thank Dr. Samuel Hellman for helpful discussions of this manuscript.Author ContributionsConceived and designed the experiments: SPP TZ RFS WZ NNK JGNG RRW. Performed the experiments: SPP TZ RFS MF EL MAB HJM HL TED SP SAK HGS WZ NNK. Analyzed the data: SPP TZ RFS WZ NNK JGNG RRW. Contributed reagents/materials/analysis tools: SPP TZ RFS WZ NNK JGNG RRW. Wrote the paper: SPP TZ RFS NNK JGNG RRW.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in North America with an overall 5-year survival rate of ,5 [1]. Previous PDAC microarray studies have revealed novel genes associated with disease progression. One of these was lipocalin-2 (LCN2), which was significantly overexpressed in PDAC cell lines and primary tumors compared to normal pancreas [2,3]. LCN2 expression was also enhanced following KRAS oncogene expression in the normal human pancreatic duct epithelial cell line H6c7 [4]. LCN2 is also known as neutrophil gelatinase-associated lipocalin (NGAL) and belongs to a diverse family of lipocalins [5]. It binds covalently and non-covalently with a wide range of macromolecules including small hydrophobic ligands, soluble extracellular macromolecules, and iron [6]. Its expression is upregulated in epithelial cells under inflammatory conditions including appendicitis, organ damage, and pancreatitis [5,7]. Overexpression of LCN2 has also been observed in a number of cancer types including breast, lung, ovary, thyroid, esophageal, and PDAC [8?2]. However, the precise role of LCN2 in cancer has not been completely 15755315 defined. The covalent complex of LCN2 and MMP-9 has been associated with enhancing invasion andmetastasis in breast cancer [12?4], poorer clinical outcome and improved migration in gastric cancer, [15,16], and increased depth of tumour invasion in esophageal cancer [11]. In addition to its role in regulating MMP-9 activity, LCN2 has also been shown to promote cell survival in A549 and MCF-7 cells when treated with phosphoinositide-dependent kinase 1 (PDK1) inhibitors [17]. Its function in iron binding and transport has recently been shown to block the induction of the pro-apoptotic protein Bim and activation of caspase-9 which attenuates apoptosis [10]. The function of LCN2 in PDAC remains unclear. In this study, we examined the expression of LCN2 in precursor lesions of various grades and tumour tissue samples to correlate expression with the pathogenesis of PDAC. We also utilised tissue culture and mouse xenograft models to examine the function of LCN2 in PDAC. Here, we report that LCN2 contributes to the invasive, angiogenic, and drug resistant phenotypes in pancreatic cancer.Materials and Methods Cell Culture and in vitro AssaysHuman PDAC cell lines, BxPC3, HPAF-II and PANC1 were obtained from the American Type Culture Collection (Manassas,LCN2 in Pancreatic CancerVA). BxPC3 was cultured in RPMI media supplemented with 10 FBS. HPAF-II and PANC1 cells were cultured in DMEM media supplemented with 10 FBS. H6c7, H6c7 KRASG12V, and H6c7KrT cell lines were generated as previously described [4]. Invasion assays were performed as pre.
